GONDOLA - 365 days in retrospect.

2.5 million research grant

The end of 2019 was a proud moment for us at Gondola Medical Technologies. We won a 2.5 million research grant from Horizon 2020 (EIC Accelerator Award) from the European Commission. This grant is a sign of trust that has helped us strengthen our activities as a company.

The GONDOLA treatment^® AMPS is a non-invasive, side-effect-free therapy for neurological conditions that cause gait and balance disorders. It helps patients regain independence, move better and live better.

The headquarters at the Biopole in Lausanne

Moving our headquarters from Ticino to the Biopôle of Lausanne is strategic for our development as a MedTech company. In fact, Biopôle is a first-class science park, renowned in Switzerland and internationally, and we are proud to be part of its life science community. Over the past year, our team has grown from 5 to 17 employees, increasing our scientific research, marketing, and sales activities.

Scope of treatment and new markets

In addition to the launch of version 3.0 of the GONDOLA device.^®designed for home use, a more user-friendly version, and scalable volumes, we have expanded the use of our AMPS treatment from Parkinson's disease alone to other neurological disorders such as stroke and cerebral palsy as well as spinal stroke and other conditions.

Geographic expansion into new markets, namely Germany, France and Spain, is well underway. At Gondola Medical Technologies, we look forward to further expanding the GONDOLA network.^® of partner centers in Germany. èer now + all we can share.

FIT's Growth Tech Loan

Gondola Medical Technologies has received the Growth Tech Loan of CHF 500,000 from FIT (Fondation pour l'innovation technologique) based at EPFL Lausanne. The loan is coming in two installments; CHF 200,000 up front, followed by CHF 300,000 based on a pivotal plan presented to the FIT selection committee. These funds will be dedicated to research and development, which includes the growth of the clinical research team and its studies.